TRACON PHARMACEUT.DL-,001 Aktie

TRACON Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases. The company products include TRC105, is an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types, TRC205 an anti-endoglin antibody that is in preclinical development for the treatment of fibrotic diseases and TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma. TRACON Pharmaceuticals was founded in October 2004 and is headquartered in San Diego, CA.